Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
Colorcon
Deloitte
Johnson and Johnson
Teva
AstraZeneca
Federal Trade Commission
Citi

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SOMAVERT

« Back to Dashboard

Clinical Trials for Somavert

Trial ID Title Status Sponsor Phase Summary
NCT00151437 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed Pfizer Phase 4 The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.
NCT00476879 Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content Completed Aarhus University Hospital N/A The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men.
NCT00476879 Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content Completed Pfizer N/A The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men.
NCT00476879 Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content Completed University of Aarhus N/A The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men.
NCT00552851 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status Pfizer Phase 4 The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year.
NCT00552851 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status University of Wuerzburg Phase 4 The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Somavert

Condition Name

Condition Name for Somavert
Intervention Trials
Acromegaly 9
Insulin Resistance 2
Prostatic Neoplasms 1
Colorectal Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Somavert
Intervention Trials
Acromegaly 9
Insulin Resistance 2
Dwarfism, Pituitary 1
Glucose Intolerance 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Somavert

Trials by Country

Trials by Country for Somavert
Location Trials
United States 6
Canada 5
Denmark 3
Germany 2
Finland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Somavert
Location Trials
California 3
Oregon 1
Tennessee 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Somavert

Clinical Trial Phase

Clinical Trial Phase for Somavert
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
Phase 2 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Somavert
Clinical Trial Phase Trials
Completed 6
Active, not recruiting 3
Recruiting 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Somavert

Sponsor Name

Sponsor Name for Somavert
Sponsor Trials
Pfizer 5
University of Aarhus 3
Aarhus University Hospital 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Somavert
Sponsor Trials
Other 17
Industry 7
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
McKinsey
Moodys
Farmers Insurance
AstraZeneca
Queensland Health
McKesson
Citi
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.